BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 5, 2025
See today's BioWorld Asia
Home
» Genfit, Sanofi-Aventis Ink $54M Deal for Metabolic Disorders
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Genfit, Sanofi-Aventis Ink $54M Deal for Metabolic Disorders
March 23, 2011
By
Marie Powers
No Comments
Extending a partnership that dates back to 1999, Genfit, of Lille, France, has inked an agreement with Sanofi-Aventis SA, of Paris, to pursue therapies for the treatment of metabolic disorders. (BioWorld International)
BioWorld Asia